Rhythm Pharmaceuticals

Rhythm Pharmaceuticals

RYTM· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +91.2% in FY2025

David Meeker is the CEO of Rhythm Pharmaceuticals and was paid $17.5M in FY2025 (Dec), up 20%.

Pay$100 in the stock at the end of FY20 → $360
CEO pay is from each Rhythm Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives5

See all
  1. 1David MeekerFY2025
  2. 2Hunter C. SmithFY2025
  3. 3Yann MazabraudFY2025
  4. 4Jennifer LeeFY2025
  5. 5Alastair GarfieldFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Rhythm Pharmaceuticals paid its 5 named executives $39.9M in total in FY2025 (Dec). CEO David Meeker was paid $17.5M of that.

Name
David MeekerChief Executive Officer
Hunter C. SmithChief Financial Officer
Yann MazabraudExecutive Vice President, Head of International
Jennifer LeeExecutive Vice President, Head of North America
Alastair GarfieldChief Scientific OfficerNot disclosedNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers20

See all

The FY2025 (Dec) proxy of Rhythm Pharmaceuticals names 20 peer companies for pay. Pay versus performance data of Rhythm Pharmaceuticals for that year is not on file, so it has no rank.

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board4

See all
  • Christophe R. JeanDirector · 10 yr on the boardIndependentAudit, Governance & Nominating—Paid as an executive
  • Jennifer GoodDirector · 6 yr on the boardIndependentAudit—Paid as an executive
  • Stuart A. ArbuckleDirector · 6 yr on the boardIndependentCompensation & Management Development, Governance & Nominating (Chair)—Paid as an executive
  • Kimberly J. PopovitsDirector · -1 yr on the boardIndependentCompensation & Management Development—Paid as an executive

The board of the latest proxy (FY2025).

Activity

  1. Pay
    Rhythm Pharmaceuticals Division head pay rose 30% to $5.6M. The stock rose 91% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Rhythm Pharmaceuticals CFO pay rose 23% to $6.2M. The stock rose 91% in FY2025 (Dec).
    DEF 14A
  3. Pay
    Rhythm Pharmaceuticals CEO pay rose 20% to $17.5M. The stock rose 91% in FY2025 (Dec).
    DEF 14A
  4. Board
    Kimberly J. Popovits joined the board of Rhythm Pharmaceuticals. Kimberly J. Popovits now sits on 3 public boards.
    3
  5. Pay
    Rhythm Pharmaceuticals Division head pay rose 223% to $5.6M. The stock rose 22% in FY2024 (Dec).
    DEF 14A
  6. Pay
    Rhythm Pharmaceuticals Division head pay fell 45% to $1.2M. The stock rose 192% in FY2022 (Dec).
    DEF 14A
  7. Pay
    Rhythm Pharmaceuticals CTO pay rose 96% to $3.4M. The stock rose 22% in FY2024 (Dec).
    DEF 14A
  8. Pay
    Rhythm Pharmaceuticals CTO pay fell 47% to $950.1K. The stock rose 192% in FY2022 (Dec).
    DEF 14A
  9. Pay
    Rhythm Pharmaceuticals Division head pay rose 105% to $4.3M. The stock rose 22% in FY2024 (Dec).
    DEF 14A
  10. Pay
    Rhythm Pharmaceuticals Division head pay fell 48% to $1.1M. The stock rose 192% in FY2022 (Dec).
    DEF 14A
  11. Pay
    Rhythm Pharmaceuticals CFO pay rose 119% to $5.1M. The stock rose 22% in FY2024 (Dec).
    DEF 14A
  12. Pay
    Rhythm Pharmaceuticals CFO pay fell 47% to $1.2M. The stock rose 192% in FY2022 (Dec).
    DEF 14A
  13. Pay
    Rhythm Pharmaceuticals CEO pay rose 103% to $14.7M. The stock rose 22% in FY2024 (Dec).
    DEF 14A
  14. Pay
    Rhythm Pharmaceuticals CEO pay fell 49% to $3.3M. The stock rose 192% in FY2022 (Dec).
    DEF 14A
  15. Pay
    Rhythm Pharmaceuticals Division head pay rose 46% to $1.7M. The stock rose 58% in FY2023 (Dec).
    DEF 14A
  16. Pay
    Rhythm Pharmaceuticals CTO pay rose 83% to $1.7M. The stock rose 58% in FY2023 (Dec).
    DEF 14A
  17. Pay
    Rhythm Pharmaceuticals Division head pay rose 94% to $2.1M. The stock rose 58% in FY2023 (Dec).
    DEF 14A
  18. Pay
    Rhythm Pharmaceuticals CFO pay rose 90% to $2.3M. The stock rose 58% in FY2023 (Dec).
    DEF 14A
  19. Pay
    Rhythm Pharmaceuticals CEO pay rose 117% to $7.2M. The stock rose 58% in FY2023 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AApr 29, 2026FY2025
Annual report10-KFeb 26, 2026FY2025
Proxy statementDEF 14AApr 29, 2025FY2024
Annual report10-KFeb 28, 2025FY2024
Proxy statementDEF 14AApr 26, 2024FY2023
Annual report10-KFeb 29, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data